Loading
Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for lung cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.
The ClinicalTrials.gov v2 API was searched on 25 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming lung cancer, non-small-cell lung cancer or small-cell lung cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed to recruitment. That returned 1,948 unique studies; the 766 already in the corpus, and the studies whose only lung involvement is a metastasis from another primary or a thymic or pleural tumour, were removed, leaving 1,075 new to the corpus.
Lung cancer has more open phase 2 trials than any other cancer, and most of them are single-centre investigator-initiated studies in one country that will never report outside a local journal. So a breadth rule is applied: every phase 3 and 2/3 trial is kept, and a phase 2 or 1/2 trial is kept only when it has an industry sponsor or collaborator, a site in the United Kingdom, or sites in three or more countries. That leaves 323 records, 146 of them phase 3 and 27 phase 2/3, carried with no outcomes, because a trial that has not reported has no result to quote.
Records link to the page the registry text names, so a trial of an EGFR inhibitor lands on the EGFR-mutant page and a trial of consolidation radiotherapy on the stage III page, and to `lung-cancer` itself only when the registry names nothing more specific. UK sites are quoted verbatim in each record's notes. Of the 1,075 trials new to the corpus, China ran 435 and the United States 271, and only eleven listed a United Kingdom site, which is a measure of how much of the current lung cancer question is being asked elsewhere.
The questions open today divide into five: whether antibody-drug conjugates can displace chemotherapy after immunotherapy fails, whether bispecific antibodies against PD-1 and VEGF beat pembrolizumab in the first line, what to do after osimertinib, whether DLL3 engagers move from third line to first in small-cell disease, and whether perioperative immunotherapy should be given before surgery, after it, or both.
Showing the technology this term belongs to: Immune checkpoint inhibitors.
Shares Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC, D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC, Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer, Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery.
Shares Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy, Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC, Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations, Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI.
Shares De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction, JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs., Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion., Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors.
Shares Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC, JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara, A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC, A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther.
Shares A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer, Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001), Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache, Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer.
Shares Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC, A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC, A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther, Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C.
Shares Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer, Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases, Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases, A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig.
Shares Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI, Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease, Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001), Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer.